These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 23157614)

  • 1. Investigation of BRAF V600E mutation in papillary thyroid carcinoma and tumor-surrounding nontumoral tissues.
    Dağlar-Aday A; Toptaş B; Oztürk T; Seyhan F; Saygili N; Eronat AP; Akadam-Teker B; Yilmaz-Aydoğan H; Aksoy F; Oztürk O
    DNA Cell Biol; 2013 Jan; 32(1):13-8. PubMed ID: 23157614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRAFV600E mutation and X-linked inhibitor of apoptosis expression in papillary thyroid carcinoma.
    Gu LQ; Li FY; Zhao L; Liu Y; Zang XX; Wang TX; Chen HP; Ning G; Zhao YJ
    Thyroid; 2009 Apr; 19(4):347-54. PubMed ID: 19355825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
    Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
    Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation.
    Huang Y; Liao D; Pan L; Ye R; Li X; Wang S; Ye C; Chen L
    Eur J Endocrinol; 2013 May; 168(5):675-81. PubMed ID: 23416953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Expression of BRAF V600E mutation in different thyroid lesions].
    Wang W; Li XH; Zhang YH; Li J; Chen J; Zhao P; Li QY; Xiang JJ; Li X; Xu RJ
    Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):354-7. PubMed ID: 21875464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
    Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
    Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study.
    Elisei R; Viola D; Torregrossa L; Giannini R; Romei C; Ugolini C; Molinaro E; Agate L; Biagini A; Lupi C; Valerio L; Materazzi G; Miccoli P; Piaggi P; Pinchera A; Vitti P; Basolo F
    J Clin Endocrinol Metab; 2012 Dec; 97(12):4390-8. PubMed ID: 23066120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantification of BRAF V600E alleles predicts papillary thyroid cancer progression.
    Kim MH; Bae JS; Lim DJ; Lee H; Jeon SR; Park GS; Jung CK
    Endocr Relat Cancer; 2014; 21(6):891-902. PubMed ID: 25266729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer.
    Jo YS; Li S; Song JH; Kwon KH; Lee JC; Rha SY; Lee HJ; Sul JY; Kweon GR; Ro HK; Kim JM; Shong M
    J Clin Endocrinol Metab; 2006 Sep; 91(9):3667-70. PubMed ID: 16772349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRAF mutation detection in indeterminate thyroid cytology specimens: underlying cytologic, molecular, and pathologic characteristics of papillary thyroid carcinoma.
    Ohori NP; Singhal R; Nikiforova MN; Yip L; Schoedel KE; Coyne C; McCoy KL; LeBeau SO; Hodak SP; Carty SE; Nikiforov YE
    Cancer Cytopathol; 2013 Apr; 121(4):197-205. PubMed ID: 22887810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of V600E BRAF mutation in papillary thyroid carcinoma in the Polish population.
    Brzeziańska E; Pastuszak-Lewandoska D; Wojciechowska K; Migdalska-Sek M; Cyniak-Magierska A; Nawrot E; Lewiński A
    Neuro Endocrinol Lett; 2007 Aug; 28(4):351-9. PubMed ID: 17693984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study.
    Elisei R; Ugolini C; Viola D; Lupi C; Biagini A; Giannini R; Romei C; Miccoli P; Pinchera A; Basolo F
    J Clin Endocrinol Metab; 2008 Oct; 93(10):3943-9. PubMed ID: 18682506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma.
    Kim TY; Kim WB; Rhee YS; Song JY; Kim JM; Gong G; Lee S; Kim SY; Kim SC; Hong SJ; Shong YK
    Clin Endocrinol (Oxf); 2006 Sep; 65(3):364-8. PubMed ID: 16918957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma.
    Lupi C; Giannini R; Ugolini C; Proietti A; Berti P; Minuto M; Materazzi G; Elisei R; Santoro M; Miccoli P; Basolo F
    J Clin Endocrinol Metab; 2007 Nov; 92(11):4085-90. PubMed ID: 17785355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The BRAF(V600E) mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome?
    Walczyk A; Kowalska A; Kowalik A; Sygut J; Wypiórkiewicz E; Chodurska R; Pięciak L; Góźdź S
    Clin Endocrinol (Oxf); 2014 Jun; 80(6):899-904. PubMed ID: 24354346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA).
    Sapio MR; Posca D; Troncone G; Pettinato G; Palombini L; Rossi G; Fenzi G; Vitale M
    Eur J Endocrinol; 2006 Feb; 154(2):341-8. PubMed ID: 16452550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Manifestations and Gene Expression in Patients with Conventional Papillary Thyroid Carcinoma Carrying the BRAF(V600E) Mutation and BRAF Pseudogene.
    Lin JD; Fu SS; Chen JY; Lee CH; Chau WK; Cheng CW; Wang YH; Lin YF; Fang WF; Tang KT
    Thyroid; 2016 May; 26(5):691-704. PubMed ID: 26914762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
    Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G
    Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid Rodolico V; Cabibi D; Pizzolanti G; Richiusa P; Gebbia N; Martorana A; Russo A; Amato MC; Galluzzo A; Giordano C
    Cancer; 2007 Sep; 110(6):1218-26. PubMed ID: 17685465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increase in Papillary Thyroid Cancer Incidence Is Accompanied by Changes in the Frequency of the BRAF V600E Mutation: A Single-Institution Study.
    Kowalska A; Walczyk A; Kowalik A; Pałyga I; Trybek T; Kopczyński J; Kajor M; Chrapek M; Pięciak L; Chłopek M; Góźdź S; Kamiński G
    Thyroid; 2016 Apr; 26(4):543-51. PubMed ID: 26889698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.